A Phase 3 interventional study of TAK-438 and Placebo in Duodenal Ulcer, sponsored by Takeda. Completed at 64 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-08-20.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Duodenal Ulcer by Takeda — none open to participants now, none under way, none of them phase 3. Duodenal Ulcer · Takeda.
Among the 18 studies in Duodenal Ulcer by Takeda, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is one of 4 that started in 2011, is one of 11 in phase 3, and was the 4th registered.
79 studies on the registry are indexed under Duodenal Ulcer; 5 are open to participants now.
Browse Duodenal Ulcer studies →None of the 18 studies in Duodenal Ulcer by Takeda is open now. The open studies under Duodenal Ulcer, anywhere →
Of the 3 Duodenal Ulcer studies recruiting now, 1 sets no upper age limit and 2 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 372 is above the median of 308 across 54 interventional studies indexed under Duodenal Ulcer.
Median enrollment 439 across the 11 interventional studies, 1,304 across the 7 observational. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Duodenal Ulcer by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the efficacy of TAK-438, once daily (QD), compared to lansoprazole in patients with duodenal ulcer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: TAK-438 · Drug: Placebo
Drug: Lansoprazole · Drug: Placebo
TAK-438 20 mg, tablets, orally, once daily for up to 6 weeks.
Lansoprazole placebo-matching capsules, orally, once daily for up to 6 weeks.
Lansoprazole 30 mg, capsules, orally, once daily for up to 6 weeks.
Also known as: AG-1749
TAK-438 placebo-matching tablets, orally, once daily for up to 6 weeks.
Endoscopic Healing Rate of Duodenal Ulcer Over 6 Weeks
Endoscopic healing rate : Rate of participants who have endoscopically confirmed all of the white coatings disappeared.
Time frame: 6 weeks
Endoscopic healing Rates of Duodenal Ulcer on Endoscopy over 4 weeks
Time frame: 4 weeks
Endoscopic healing Rates of Gastric Ulcer on Endoscopy at week 2
Time frame: 2 weeks
Change from Baseline in the Incidence of Gastrointestinal Symptoms Associated with Duodenal Ulcer
Time frame: Baseline and 6 weeks
The record gives a start of Oct 2011, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonoprazan